| Humira (adalimumab) / AbbVie |
NCT02492217: Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients |
|
|
| Completed | 4 | 69 | Europe | Adalimumab | Universidade Nova de Lisboa | Ankylosing Spondylitis | 05/18 | 05/18 | | |
PREDICTRA, NCT02198651 / 2014-001114-26: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects |
|
|
| Completed | 4 | 149 | Canada, US, Europe, RoW | Adalimumab, ABT-D2E7, Humira, Placebo | AbbVie | Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases | 05/18 | 08/18 | | |
2013-004406-25: Biomarkers identification of efficacy in Ankylosing Spondylitis |
|
|
| Completed | 4 | 70 | Europe | Humira, Solution for injection, Humira | Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Abbvie | Ankylosing Spondylitis, Ankylosing Spondylitis, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2015-000943-17: Dose decrease of biologics for psoriasis Dosis afbouwen van biologics voor psoriasis |
|
|
| Completed | 4 | 120 | Europe | Injection, Humira (adalimumab), Enbrel (etaneracept), Stelara (ustekinumab) | Radboudumc, Zonmw | Adult Patients diagnosed psoriasis vulgaris Volwassenen gediagnosticeerd met psoriasis vulgaris, Psoriasis Psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT02602925: Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity |
|
|
| Completed | 4 | 120 | Europe | Dose decrease, Usual care | Radboud University Medical Center, ZonMw: The Netherlands Organisation for Health Research and Development | Psoriasis | 07/18 | 07/18 | | |
| Completed | 4 | 566 | Europe, Canada, RoW | Ixekizumab, LY2439821, Adalimumab | Eli Lilly and Company | Psoriatic Arthritis | 11/18 | 09/19 | | |
|
| Unknown status | 4 | 120 | Canada | Adalimumab, Humira | Université de Sherbrooke, AbbVie | RheumatoId Arthritis | 12/18 | 12/19 | | |
2015-004173-32: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. Individualiseret behandling: dosering af TNF-alfa hæmmende behandling efter serumkoncentrationsmålinger. |
|
|
| Completed | 4 | 500 | Europe | Solution for injection/infusion in pre-filled syringe, Solution for infusion, Enbrel, Humira, Remsima, Benepali, Remicade | Department of Clinical Biochemestry, Aarhus University Hospital, Aarhus University Hospital | Rheumatic diseases, Rheumatic diseases, Body processes [G] - Immune system processes [G12] | | | | |
2018-002925-47: prediction of response to therapy in inflammatory bowel disease Predicción de respuesta al tratamiento en la enfermedad inflamatoria intestinal |
|
|
| Ongoing | 4 | 180 | Europe | Injection, Infusion, Adalimumab, Infliximab, Golimumab, Ustekinumab, Vedolizumab | Fundación de Investigación Biomédica del Hospital Universitario de La Princesa, Instituto de Salud Carlos III | Inflammatory bowel disease Enfermedad inflamatoria intestinal, Corhn´s disease and ulcerative colitis Enfermedad de Crohn y colitis ulcerosa, Diseases [C] - Digestive System Diseases [C06] | | | | |
PAILOT, NCT02256462: Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment () Trial |
|
|
| Completed | 4 | 82 | RoW | Adalimumab, Humira | Schneider Children's Medical Center, Israel | Crohn's Disease | 01/19 | 01/19 | | |
| Withdrawn | 4 | 0 | NA | Adalimumab | McMaster University | Crohn Disease, Ulcerative Colitis | 02/19 | 09/19 | | |
2018-002064-15: Patient preference model: treatment of perianal fistulas in Crohn's disease |
|
|
| Terminated | 4 | 140 | Europe | Infliximab, Adalimumab, Powder for concentrate and solution for solution for infusion, Powder for concentrate for solution for infusion, Remicade, Humira | Academic Medical Center, Academic Medical Center | Perianal fistulas in Crohn's Disease, Perianal fistulas in Crohn's Disease, Diseases [C] - Digestive System Diseases [C06] | | | | |
| Completed | 4 | 206 | Europe, Canada, US, RoW | Placebo, Adalimumab, Humira | AbbVie | Hidradenitis Suppurativa (HS) | 05/19 | 10/19 | | |
| Unknown status | 4 | 90 | Europe | addition of azathioprine, Switch to a second anti-TNF drug alone | Védrines, Philippe, M.D. | Clinical Failure After Switch | 06/19 | 06/20 | | |
2017-004588-11: Control Crohn Safe Trial: Long term outcome and tolerability of six months adalimumab as initial treatment for newly diagnosed Crohn's disease versus standard step-up treatment. Veilige controle van de ziekte van Crohn trial: Lang termijn effectiviteit en veiligheid van 6 maanden behandeling met adalimumab versus standaard step-up behandeling van nieuwe patiënten met de ziekte van Crohn. |
|
|
| Ongoing | 4 | 158 | Europe | Suspension for injection in pre-filled pen, Humira | University Maastricht, ZonMW | The chronic inflammatory bowel disease Crohn's disease De chronische inflammatoire darmaandoening de ziekte van Crohn, Chronic inflammatory disease of the bowel Crohn's disease De chronische darmontsteking de ziekte van Crohn, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT03827876: Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis |
|
|
| Unknown status | 4 | 30 | US | Enstilar 0.005%-0.064% Topical Foam | Psoriasis Treatment Center of Central New Jersey, LEO Pharma | Psoriasis | 09/19 | 12/19 | | |
NCT02814175 / 2016-000191-21: A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL) |
|
|
| Completed | 4 | 246 | Europe, Canada, US, RoW | methotrexate (MTX), adalimumab (ADA) | AbbVie | Psoriatic Arthritis | 09/19 | 03/20 | | |
NCT02242474: Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis |
|
|
| Unknown status | 4 | 660 | Canada | Anti-TNF suspended perioperatively, Infliximab, Remicade, Etanercept, Enbrel, Adalimumab, Humira, Certolizumab, Cimzia, Golimumab, Simponi, Anti-TNFα continued perioperatively | CHU de Quebec-Universite Laval | Rheumatoid Arthritis | 10/19 | 10/19 | | |
2019-000412-29: Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST) |
|
|
| Not yet recruiting | 4 | 118 | Europe | Humira, Solution for injection in pre-filled syringe, Humira | F.I. Proctor Foundation, University of California San Francisco, National Eye Institute, National Institutes of Health | juvenile-idiopathic arthritispaediatric uveitis, Inflammation of the joints and eyes, Diseases [C] - Eye Diseases [C11] | | | | |
2019-001754-25: Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment |
|
|
| Completed | 4 | 84 | Europe | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab, Injection, Enbrel, Benepali, Erelzi Rituximab: mabthera, Rixathon, Truxima Abatacept: Orencia Tocilizumab: Roactemra Sarilumab: Kevzara | Reade, ZonMw | rheumatoid arthritis, Rheumatoid arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT02878161: Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" |
|
|
| Unknown status | 4 | 240 | NA | methotrexate(necessary), MTX, infliximab, IFX, etanercept, ETN, adalimumab, ADA, leflunomide (permitted, not necessary), LEF, NSAIDs (permitted,not necessary), non steroidal anti inflammatory drugs, Glucocorticoids (permitted,not necessary), prednisone,methylprednisolone,etc. | Fen Li | Rheumatoid Arthritis | 12/19 | 12/19 | | |
| Ongoing | 4 | 60 | Europe | Abatacept, Humira, Injection, Abatacept, Humira | St George's, University of London | Rheumatoid arthritis, Rheumatoid disease, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
2017-000435-13: Clinical trial to examine changes in inflammational type of active, moderate-to-severe hidradenitis suppurativa during a 6-week treatment with the approved medication Adalimumab (HUMIRA). |
|
|
| Completed | 4 | 15 | Europe | HUMIRA, Solution for injection in pre-filled syringe, HUMIRA | University Hospital Frankfurt for its Dermatology Department, Clinical Research, AbbVie Deutschland GmbH | Hidradenitis suppurativa is defined as a chronic inflammatory disease of the intertriginous area, including the axilla, groin and anogenital or submammary regions. The condition is characterized by inflammation, recurrent abscesses, fistulas and sinus tracts, leading to post-inflammatory contracture and accordion-like mutilating scars. Mostly this disease appears in younger patients from 15 - 45 years and is connected with a high burden of disease and decreased quality of life., Hidradenitis suppurativa is a chronic skin disease which affects the axilla and groin. This disease is common and furthermore connected with a low quality of life and other organic comorbidity., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 4 | 1095 | Europe, Canada, US | Enhanced Treatment Algorithm, Adalimumab, Conventional Step-care Algorithm | Alimentiv Inc. | Crohn's Disease | 04/20 | 04/20 | | |
2016-001566-28: Identifying mediators in patients with hidradenitis supportive |
|
|
| Terminated | 4 | 32 | Europe | HUMIRA, Solution for injection, HUMIRA | University College Dublin, Science Foundation Ireland | Hidradenitis Suppurativa, Rare skin disease, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Active, not recruiting | 4 | 290 | US | Etanercept, Enbrel, Infliximab, Remicade, Adalimumab, Humira, Placebo | Georgetown University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Maryland, Baltimore, Washington D.C. Veterans Affairs Medical Center, Medstar Health Research Institute, Patient-Centered Outcomes Research Institute, Arthritis and Pain Associates of PG County, Arthritis & Rheumatism Associates, P.C., Rheumatology Associates of Baltimore, L.L.C., The Arthritis Clinic of Northern Virginia, P.C., Arthritis and Rheumatic Disease Associates, P.C. | Rheumatoid Arthritis | 06/24 | 08/24 | | |
2013-004918-18: Optimising adalimumab treatment in psoriasis with concomitant methotrexate. |
|
|
| Completed | 4 | 100 | Europe | METHOTREXATE, HUMIRA, Tablet, methotrexate | Academic Medical Center, Ghent University Hospital, Deparment of dermatology, Academic Medical Center, Department of dermatology, Academic Medical Center, Department of dermatology, Ghent University Hospital | psoriasis, psoriasis, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT03737708: A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) |
|
|
| Completed | 4 | 21 | RoW | tacrolimus, FK506, Prograf, methotrexate, adalimumab, tocilizumab, abatacept | Astellas Pharma Korea, Inc. | Rheumatoid Arthritis (RA) | 06/20 | 06/20 | | |
ChiCTR2000030089: A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) |
|
|
| Not yet recruiting | 4 | 60 | | Conventional treatent and adalimumab ;conventional treatment | Shanghai Changzheng Hospital; Shanghai Changzheng Hospital, Shanghai Changzheng Hospital Project Fund and Drug donation from Bio-Thera Solutions, Ltd. | Novel Coronavirus Pneumonia（COVID-19） | | | | |
| Active, not recruiting | 4 | 78 | RoW | Adalimumab Injection, Thiopurine, Endoscopic balloon dilatation | St Vincent's Hospital Melbourne, Australasian Gastro Intestinal Research Foundation, AbbVie | Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel | 09/20 | 09/21 | | |
| Terminated | 4 | 40 | Europe | bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept), Enbrel, Humira, Remicade, Cimzia, Simponi, Roactemra, Orencia | Medical University of Graz | Rheumatoid Arthritis | 11/20 | 11/20 | | |
NCT03306446: Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab |
|
|
| Active, not recruiting | 4 | 203 | Europe | Start adalimumab in monotherapy, begin humira in monotherapie in Early crohn disease patient | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | CD | 03/21 | 03/25 | | |
| Completed | 4 | 159 | US | Methotrexate, Rheumatrex, Sulfasalazine, Azulfidine, Hydroxychloroquine, Plaquenil, Etanercept, enbrel, Adalimumab, Humira | Brigham and Women's Hospital, Columbia University | Arthritis, Rheumatoid | 05/21 | 05/21 | | |
NCT03505008: Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan |
|
|
| Completed | 4 | 300 | Japan, RoW | Methotrexate, MTX, Adalimumab, ADA | Keio University, Eisai Co., Ltd. | Rheumatoid Arthritis | 05/21 | 05/21 | | |
2018-003432-72: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij patiënten met Artritis Psoriatica en Axiale Spondylartritis. |
|
|
| Completed | 4 | 234 | Europe | Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, Solution for injection/infusion, Tumor Necrosis Factor alpha (TNF-a) Inhibitors: Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab | Sint Maartenskliniek, Sint Maartenskliniek | Adults diagnosed with Psoriatic Arthritis en Axial Spondyloarthritis. Volwassenen gediagnosticeerd met artritis psoriatica en axiale spondylartritis., Psoriatic arthritis and Axial Spondyloarthritis Artritis psoriatica en axiale spondylartritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-002211-65: EFFECT OF TOFACITINIB ON COAGULATION EFECTO DE TOFACITINIB SOBRE LA COAGULACIÓN |
|
|
| Ongoing | 4 | 60 | Europe | Injection, Infusion, Pastille, Adalimumab, Infliximab, Golimumab, Tofacitinib | Fundación Española de Gastroenterología, pfizer | ulcerative colitis colitis ulcerosa, ulcerative colitis colitis ulcerosa, Body processes [G] - Biological Phenomena [G16] | | | | |
| Terminated | 4 | 11 | US | Abatacept, Orencia, Adalimumab, Humira | Columbia University, Bristol-Myers Squibb | Rheumatoid Arthritis, Myocardial Inflammation | 09/21 | 09/21 | | |
| Completed | 4 | 192 | Europe | Methotrexate, Adalimumab, humira, Azathioprine / 6 Mercaptopurine, imurel / purinethol | PIBD-Net, European Commission | Crohn's Disease | 06/21 | 06/21 | | |
| Terminated | 4 | 208 | Europe | Tocilizumab, Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab Pegol | Mario Negri Institute for Pharmacological Research | Rheumatoid Arthritis | 12/21 | 12/21 | | |
ADDORA, NCT04194827: Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring |
|
|
| Recruiting | 4 | 267 | Europe | Adalimumab serum trough concentration, Disease activity, Adalimumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 12/24 | 12/24 | | |
| Completed | 4 | 139 | Europe | Anti-TNF: Infliximab (Infusion), Anti-TNF discontinuation: Physiological saline solution, Anti-TNF:Adalimumab (Subcutaneus) | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis | 12/21 | 12/22 | | |
| Completed | 4 | 78 | Europe | Dose reduction to 2mg/L, Dose reduction to 5mg/L, Adalimumab | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 09/23 | 09/23 | | |
ADDORA-switch, NCT04251741: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment |
|
|
| Active, not recruiting | 4 | 86 | Europe | Adalimumab trough concentration, Usual care | Reade Rheumatology Research Institute, ZonMw: The Netherlands Organisation for Health Research and Development, Sint Maartenskliniek | Rheumatoid Arthritis | 05/24 | 05/24 | | |
ChiCTR2100044045: Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases including rheumatoid arthritis, ankylosing spondylitis and psoriasis |
|
|
| Recruiting | 4 | 50 | | Adalimumab | Mianyang Hospital of Traditional Chinese Medicine; Mianyang Hospital of Traditional Chinese Medicine, None | Immune-Mediated Inflammatory Diseases | | | | |
2019-001918-42: A non-inferiority study on dose reduction of adalimumab in psoriasis patients who are overtreated. |
|
|
| Completed | 4 | 160 | Europe | Adalimumab, Solution for injection in pre-filled syringe, Solution for injection in pre-filled pen, Humira 40 mg oplossing voor injectie in voorgevulde spuit, Humira 40 mg oplossing voor injectie in voorgevulde pen | Ghent University Hospital, Ghent University Hospital | Patients with moderate-to-severe psoriasis., Patients with moderate-to-severe psoriasis., Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT05683054: A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated |
|
|
| Completed | 4 | 19 | Europe | Dose tapering of adalimumab in patients with supratheurapeutic serum trough levels, Venapuncture, Dermatology Life Quality Index (DLQI), EQ-5D-5L questionnaire, Dried blood spot sampling | University Hospital, Ghent, KU Leuven | Psoriasis | 03/22 | 08/22 | | |
| Terminated | 4 | 19 | Europe | Venapuncture, Dried blood spot, Dose reduction | University Hospital, Ghent, KU Leuven, University Ghent | Psoriasis Vulgaris | 03/22 | 03/22 | | |
NCT04300686: A Pilot Study in Severe Patients With Takayasu Arteritis. |
|
|
| Recruiting | 4 | 40 | RoW | Tocilizumab, IL-6R alpha antibody, Adalimumab, TNF-alpha antibody | Shanghai Zhongshan Hospital | Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment | 05/22 | 12/23 | | |
NCT05015335: The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage |
|
|
| Recruiting | 4 | 50 | RoW | Adalimumab, ADA, Methotrexate, MTX | Peking Union Medical College Hospital | Uveitis, Anterior, Adalimumab | 07/22 | 07/23 | | |
| Unknown status | 4 | 128 | Europe | Wide Excision, Adalimumab Injection, Humira | Erasmus Medical Center, Prothya Biosolutions | Hidradenitis Suppurativa | 07/22 | 07/22 | | |
NCT04132388: Hidradenitis Suppurativa Patient Experience With Humira Treatment |
|
|
| Withdrawn | 4 | 0 | US | Electronic Reporting, Adalimumab, Humira | Wake Forest University Health Sciences | Hidradenitis Suppurativa | 09/22 | 09/22 | | |
ChiCTR2000036845: A single-center, randomized, controlled study on the effect of proactive therapeutic drug monitoring on the efficacy and cost of adamumab in the treatment of Crohn's disease |
|
|
| Not yet recruiting | 4 | 120 | | In the proactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Adalimumab serum trough concentration is going to be monitored at week 8, 16, 24, 32 and 40 after inclusion: 1.If serum trough concentration≥11.7 g/ mL, continue&# ;In the reactive TDM group, adamumab is 160mg at week 0, 80mg at week 2, and 40mg once every two weeks from week 4 until week 8. Clinical response is assesed at week 8, 16, 24, 32, and 40 after inclusion: 1.If the clinical response is achieved, continue to administer 40mg once every | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Xinhua hospital affiliated to Shanghai jiaotong university school of medicine, Special funds | Crohn's disease | | | | |
| Active, not recruiting | 4 | 174 | Europe | Lengthening adalimumab dosing interval, Lengthening Humira dosing interval, Longer adalimumab interval, Longer Humira interval, Adalimumab dose reduction, Humira dose reduction | Radboud University Medical Center, Erasmus Medical Center | Crohn Disease in Remission, Crohn Disease | 10/22 | 10/22 | | |
| Completed | 4 | 18 | Europe | Abatacept Injection, Orencia, Adalimumab Injection, Humira | St George's, University of London | Rheumatoid Arthritis | 10/22 | 10/22 | | |
ChiCTR2100049326: A Prospective, Single-arm Clinical Study of the Efficacy and Safety of Adalimumab Incremental Therapy in Patients With Fistulizing Crohn's Disease |
|
|
| Recruiting | 4 | 60 | | Adalimumab, every 2 weeks, 40mg each time, 12 weeks of treatment ;Adalimumab, once every 2 weeks, each time 80mg, 12 weeks of treatment ;Adalimumab, every 2 weeks, 40mg each time, 12 weeks of treatment. Azathioprine, 1.5-4mg/kg/day, course of treatment for 12 weeks | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self-financed | fistulizing Crohn's disease | | | | |
METHOBIO, NCT02829424: Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis |
|
|
| Terminated | 4 | 78 | Europe | Methotrexate, Methotrexate Placebo | Assistance Publique Hopitaux De Marseille | Psoriasis | 01/23 | 02/24 | | |
ChiCTR2100043791: Efficacy observation and safety and tolerability evaluation of adalimumab combined with isotretinoin in the treatment of severe and aggregated acne |
|
|
| Recruiting | 4 | 20 | | Adalimumab + Isotretinoin ;Isotretinoin | Dermatology Hosipital of Southern Medical University; Dermatology Hosipital of Southern Medical University, Self-financing | Severe acne and acne conglobata | | | | |
BACH, NCT04985435: Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA |
|
|
| Recruiting | 4 | 100 | Europe | Filgotinib, Jyseleca, Anti-Tumor Necrosis Factor Alpha Drug (Product), Adalimumab (Humira) Etanercept (Enbrel), 50 patients will have a Free Choice between Filgotinib and anti TNF | R.Bos, Galapagos NV, Frisius Medisch Centrum, Leiden University Medical Center | Rheumatoid Arthritis | 09/25 | 09/25 | | |
ChiCTR2100045463: Efficacy and safety of Adalimumab in refractory intestinal Behcet’s disease: A single-center, interventional, open-label, single-arm study |
|
|
| Recruiting | 4 | 30 | | adalimumab | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, none | intestinal Beh?et's disease | | | | |
NCT05153200: Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study. |
|
|
| Not yet recruiting | 4 | 40 | NA | Upadacitinib, Rinvoq, Adalimumab, Idacio | Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa | Rheumatoid Arthritis | 06/23 | 06/23 | | |
ChiCTR2200055876: Efficacy and safety of Iguratimod combined with adalimumab in active rheumatoid arthritis with poor response to csDMARDs |
|
|
| Recruiting | 4 | 98 | | IGU 25mg bid + adalimumab 40mg q2w | Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong Provincial Hospital Affiliated to Shandong First Medical University | Rheumatoid Arthritis | | | | |
NCT03739853: Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial |
|
|
| Completed | 4 | 192 | Europe | Methotrexate, Sulfasalazine, Leflunomide, Adalimumab | University of Oxford | Psoriatic Arthritis | 10/24 | 10/24 | | |
NCT05313620: Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events |
|
|
| Recruiting | 4 | 30 | Europe | Tofacitinib, Infliximab Adalimumab y Golimumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Ulcerative Colitis, Thromboembolism | 12/25 | 12/25 | | |
BioIBD, NCT03885713: Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease |
|
|
| Completed | 4 | 180 | Europe | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis | 12/24 | 12/24 | | |
NCT05180526: Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV) |
|
|
| Active, not recruiting | 4 | 60 | RoW | QLETLI | Bio-Thera Solutions | Uveitis | 12/24 | 12/24 | | |
| Active, not recruiting | 4 | 250 | RoW | biologic DMARDs, rimicade, adalimumab | Kasr El Aini Hospital | Juvenile Idiopathic Arthritis Associated Uveitis | 12/23 | 04/24 | | |
| Active, not recruiting | 4 | 15 | Canada | Tapered doses of TNFi, etanercept 50 mg every 10 days (75% of baseline dose), 14 days (50%), 30 days (25%), adalimumab 40 mg every 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), certolizumab pegol 200 mg 3 weeks (75%), 4 weeks (50%), 16 weeks (25%), golimumab 50 mg every 6 weeks (75%), 8 weeks (50%), 16 weeks (25%), infliximab 5 mg/kg every 8 weeks (75%), 12 weeks (50%), 16 weeks (25%), Standard dose of TNFi, etanercept 50 mg every 7 days, adalimumab 40 mg every 2 weeks, certolizumab pegol 200 mg every 2 weeks, golimumab 50 mg every 4 weeks, infliximab 5 mg/kg every 6 weeks | University Health Network, Toronto | Axial Spondyloarthritis | 07/24 | 08/24 | | |
| Completed | 4 | 841 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 04/24 | 05/24 | | |
ChiCTR2200058839: Evaluation the efficacy and safety of reduced-dose adalimumab in Chinese patients with rheumatoid arthritis (RA): A Multicenter, prospective, parallel-group, real-world study |
|
|
| Not yet recruiting | 4 | 343 | | Treatment of adalimumab ;Treatment of adalimumab ;Treatment of adalimumab ;Treatment of adalimumab | The Second Affiliated Hospital Of Nanchang University; The Second Affiliated Hospital of Nanchang University, Biothera Solutions, formerly as Sinoasis Pharma, Ltd. | Rheumatoid arthritis | | | | |
| Recruiting | 4 | 158 | Europe | Adalimumab, Humira, standard step-up care | Maastricht University Medical Center, Maastricht University, ZonMw: The Netherlands Organisation for Health Research and Development | Crohn Disease, Inflammatory Bowel Diseases | 05/24 | 09/26 | | |
NCT03591770: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib |
|
|
| Terminated | 4 | 15 | US | SHINGRIX, Recombinant zoster vaccine | Boston Medical Center | Inflammatory Bowel Diseases | 07/24 | 07/24 | | |
| Completed | 4 | 200 | Europe | Humira, Injection, Adalimumab | GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives, GETAID, GETAID | Crohn's disease, Crohn's disease, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
NCT05414201: A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis |
|
|
| Completed | 4 | 87 | RoW | Adalimumab, Humira | AbbVie | Non-infectious Intermediate Posterior- or Pan-uveitis | 06/24 | 06/24 | | |
NCT06498089: A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis |
|
|
| Recruiting | 4 | 124 | RoW | Prednisone, Glucocorticoids, Methotrexate, MTX, Tocilizumab, TCZ, Tofacitinib, TOF, Adalimumab, ADA | Shanghai Zhongshan Hospital | Takayasu Arteritis | 06/26 | 06/27 | | |
FILRA, NCT06527534: Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA) |
|
|
| Recruiting | 4 | 30 | Europe | Filgotinib, Adalimumab | Universita di Verona | Rheumatoid Arthritis | 07/25 | 09/25 | | |
RA-DRUM, NCT06440629: Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial |
|
|
| Recruiting | 4 | 350 | Europe | Therapeutic drug monitoring (TDM) of adalimumab | Diakonhjemmet Hospital, Oslo University Hospital, Karolinska University Hospital, Queen Mary University of London, Medical University of Vienna, Alesund Hospital, St. Olavs Hospital, Helse Stavanger HF, Drammen sykehus, University Hospital of North Norway, Førde Hospital Trust, Hospital of Southern Norway Trust, Haukeland University Hospital, Ostfold Hospital Trust, Lillehammer Hospital for Rheumatic Diseases, Vestre Viken Hospital Trust, Haugesund Rheumatism Hospital, Betanien Hospital, Helgeland Hospital Trust, Nordlandssykehuset HF, Carol Davila University of Medicine and Pharmacy, Humanitas Research Hospital IRCCS, Rozzano-Milan, Sahlgrenska University Hospital | Rheumatoid Arthritis | 12/27 | 12/27 | | |
VEDIAN, NCT06180382: Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. |
|
|
| Recruiting | 4 | 220 | Europe | Adalimumab, Vedolizumab | Centre Hospitalier Universitaire de Saint Etienne, Takeda France | Crohn's Disease | 01/26 | 01/27 | | |
ROC-SPA, NCT03445845: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis |
|
|
| Completed | 4 | 300 | Europe, RoW | Secukinumab, TNF blocker, blood specimen | Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France | Axial Spondyloarthritis | 09/24 | 10/24 | | |
ChiCTR2200067227: A randomized, multicenter, positive drug controlled clinical study protocol to evaluate the efficacy and safety of adalimumab in adults with exanthematous and severe drug eruptions |
|
|
| Not yet recruiting | 4 | 160 | | Adalimumab ;Methylprednisolone | The University of Hong Kong-Shenzhen Hospital; The University of Hong Kong-Shenzhen Hospital, None | drug eruption | | | | |
MONITORA, NCT06528431: Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the Study |
|
|
| Recruiting | 4 | 180 | Europe | Clinical tapering strategy, Step Wedge trial | Centre Hospitalier Universitaire de Saint Etienne, AAP MESSIDOR | Arthritis, Rheumatoid | 09/26 | 12/27 | | |
ChiCTR2300072687: A real world study of does reduction for adalimumab in Chinese patients with ankylosing spondylitis in low disease activity-a prospective multicenter cohort study |
|
|
| Not yet recruiting | 4 | 400 | | Treatment of adalimumab ;Treatment of adalimumab | First Affiliated Hospital of Chengdu Medical College, Chengdu, China; First Affiliated Hospital of Chengdu Medical College, Chengdu, China, self-funded | ankylosing spondylitis | | | | |
| Completed | 4 | 1317 | US | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 05/25 | 05/25 | | |
NCT05527444: The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients |
|
|
| Active, not recruiting | 4 | 100 | RoW | Secukinumab 150 mg/ml, Secukinumab, Adalimumab Ab, Adalimumab, NSAID, Thalidomide Pill | Qilu Hospital of Shandong University | Ankylosing Spondylitis | 12/24 | 12/24 | | |
ChiCTR1900027147: Efficacy and safety of adalimumab in Behcet's disease-related uveitis |
|
|
| Not yet recruiting | 4 | 30 | | Adalimumab | State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, None | Behcet's disease-related uveitis | | | | |
2019-002942-19: Nordic study of treatment strategy in inflammatory bowel disease Nordisk studie av behandlingsstrategi vid inflammatorisk tarmsjukdom |
|
|
| Completed | 4 | 300 | Europe, RoW | Powder for concentrate for solution for infusion, Solution for injection in pre-filled pen, Film-coated tablet, Tablet, Remicade Infliximab, Humira Adalimumab, Imurel Azatioprin, Puri-nethol Merkaptopurin | Region Örebro län, VINNOVA | Crohn's disease and Ulcerative colitis, Crohn's disease and Ulcerative colitis, Diseases [C] - Digestive System Diseases [C06] | | | | |
2005-001826-99: DANISH – a DANish multicenter study of new Imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic outcome in Spondyloarthritis patients receiving Humira |
|
|
| Completed | 4 | 60 | Europe | Humira, Adalimumab, Injection | Hvidovre Hospital, Dept. of Rheumatology | Spondyloarthritis | | | | |
NCT06833112: Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis |
|
|
| Not yet recruiting | 4 | 10 | RoW | Secukinumab, Adalimumab | The Affiliated Hospital Of Guizhou Medical University | Ankylosing Spondylitis | 08/27 | 02/28 | | |
ChiCTR2300074783: Evaluation the efficacy and safety of adalimumab injection (SCT630) with rheumatoid arthritis (RA): A multicenter, prospective, real-world study |
|
|
| Not yet recruiting | 4 | 200 | | NA | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Beijing Kangwei Institute of Biological Health Sciences | Rheumatoid arthritis | | | | |
ChiCTR2400086895: A pilot study of methotrexate combined with adalimumab in the treatment of Meniere's disease |
|
|
| Not yet recruiting | 4 | 30 | | Adalimumab 40mg 0.8ml, once every 4 weeks, lasting for 16 weeks;Administer 10mg of methotrexate tablets orally after meals, once a week, for 16 weeks | Shandong Second Provincial General Hospital(Shandong Provincial ENT Hospital, Shandong ENT Institute); Shandong Second Provincial General Hospital(Shandong Provincial ENT Hospital, Shandong ENT Institute), Self raised by the department | Meniere's disease | | | | |
| Not yet recruiting | 4 | 40 | Europe | Filgotinib, Jyseleca, Adalimumab, Hyrimoz | Leiden University Medical Center, Galapagos NV | Rheumatoid Arthritis | 03/25 | 10/25 | | |
ChiCTR2400081637: A prospective, multicenter real-world study of Adalimumab injection (Anjiarun) in the treatment of ankylosing spondylitis |
|
|
| Recruiting | 4 | 200 | | | Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital, Beijing Kangwei Institute of Biological Health Sciences | Ankylosing spondylitis | | | | |
NCT04183608 / 2018-003490-10: A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab |
|
|
| Recruiting | 4 | 238 | Europe | Adalimumab, Calprotectin, e-Monitoring, Therapy Education | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, AbbVie | Ulcerative Colitis | 04/25 | 05/28 | | |
| Completed | 4 | 2663 | Europe, US, RoW | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 05/25 | 05/25 | | |
NCT03816397: Adalimumab in JIA-associated Uveitis Stopping Trial |
|
|
| Completed | 4 | 87 | Europe, US, RoW | Adalimumab, HUMIRA, Placebo | Nisha Acharya, Children's Hospital of Philadelphia, Children's Hospital Medical Center, Cincinnati, Children's Mercy Hospital Kansas City, National Eye Institute (NEI), Great Ormond Street Hospital for Children NHS Foundation Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Alder Hey Children's NHS Foundation Trust, Newcastle-upon-Tyne Hospitals NHS Trust, Sheffield Children's NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Royal Children's Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust, Vanderbilt University Medical Center, University of California, Davis, University of Texas at Austin, University of Miami, University Hospitals, Leicester, University of Utah, Colorado Retina Associates, Manchester University NHS Foundation Trust | Uveitis, JIA | 01/25 | 04/25 | | |
SMOOTH, NCT06390436: Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis |
|
|
| Not yet recruiting | 4 | 320 | Europe | Blood sample, Adalimumab Injection | Centre Hospitalier Universitaire de Saint Etienne, Direction Générale de l'Offre de Soins | Uveitis, Chronic Disease | 05/28 | 05/29 | | |
| Not yet recruiting | 4 | 50 | RoW | Deucravacitinib, Adalimumab | Chinese SLE Treatment And Research Group | Takayasu Arteritis (TAK) | 12/27 | 03/28 | | |
NCT05626348: The Clinical Efficacy of Immunomodulators in RA Patients |
|
|
| Recruiting | 4 | 400 | RoW | Iguratimod, IGU, T-614, Methotrexate, MTX, Adalimumab Injection, adalimu, Leflunomide, LEF, Hydroxychloroquine, HCQ | Qilu Hospital of Shandong University | Arthritis, Rheumatoid | 06/25 | 12/26 | | |
| Not yet recruiting | 4 | 270 | | Interferon Alpha-2a ;Adalimumab ;Cyclosporine | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Raise independently | Uveitis in Behcet's Disease | | | | |
SMILE, NCT07149792: A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers |
|
|
| Recruiting | 4 | 50 | RoW | Prescreen platform, biologics treatment | Taichung Veterans General Hospital, Chang Gung Memorial Hospital, Chung Shan Medical University, Far Eastern Memorial Hospital, China Medical University Hospital | Psoriasis, Psoriasis Arthritis, Biologics | 12/26 | 06/28 | | |
ChiCTR2400079755: An open randomized controlled trial of Upadacitinib to improve anxiety in patients with psoriatic arthritis |
|
|
| Recruiting | 4 | 40 | | Upadacitinib (15 mg/day, qd); adalimumab (40 mg/time, once every two weeks) | Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine; Shenzhen Traditional Chinese Medicine Hospital, self-finance | Psoriatic arthritis anxiety disorder | | | | |
